Venus Remedies Limited (VENUSREM) Price & Analysis

Compare

1 Followers

VENUSREM Stock Chart & Stats

₹782.25

-₹3.85(-1.26%)

At close: Jan 08 4:00 PM EST

₹782.25

-₹3.85(-1.26%)

Day’s Range― - ―

52-Week Range₹277.85 - ₹872.80

Previous CloseN/A

Volume28.34K

Average Volume (3M)2.33K

Market Cap

₹10.06B

Enterprise Value₹10.23B

Total Cash (Recent Filing)₹1.56B

Total Debt (Recent Filing)₹0.00

Price to Earnings (P/E)13.8

Beta1.04

Next Earnings

Jun 03, 2026

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)19.14

Shares Outstanding13,366,988

10 Day Avg. Volume2,529

30 Day Avg. Volume2,330

Financial Highlights & Ratios

PEG Ratio0.16

Price to Book (P/B)0.75

Price to Sales (P/S)0.65

P/FCF Ratio5.20

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price TargetN/A

Price Target UpsideN/A

Rating ConsensusN/A

Number of Analyst Covering0

EPS Forecast (FY)N/A

Revenue Forecast (FY)N/A

Bulls Say, Bears Say

Bulls Say

Strong Cash GenerationA robust free cash flow trend and high operating-CFO-to-net-income conversion indicate durable internal funding. This strengthens capacity to fund working capital, regulatory registrations, plant upkeep and selective investments without adding leverage, supporting sustainable operations.

Conservative Balance SheetHigh equity ratio and low financial leverage reduce solvency risk and preserve optionality for capex or acquisitions. Improving ROE shows capital is being deployed more efficiently, enhancing resilience through industry cycles and enabling strategic long-term initiatives.

Improving Profitability TrendsConsistent top-line growth with expanding gross and net margins plus solid EBITDA/EBIT performance demonstrates improving unit economics and operational leverage. That supports sustainable profitability across hospital and export channels and funds reinvestment in core products.

Bears Say

Product And Customer ConcentrationHeavy focus on hospital/critical-care anti-infectives concentrates revenue in a narrow therapeutic and customer set. This increases exposure to hospital tender dynamics, formulary changes, pricing pressure and regulatory shifts, which can amplify downside in adverse cycles.

Moderate Revenue Growth RateMid-single-digit revenue growth, while positive, is modest relative to faster-growing specialty peers. Without accelerated product launches or geographic diversification, top-line expansion may constrain long-term EPS and market-share gains absent inorganic initiatives or stepped-up innovation.

No Dividend YieldLack of dividend distribution reduces appeal to income-oriented shareholders and narrows investor base. Even with strong cash flow, absence of a payout can limit total-return attractiveness versus dividend-paying peers and place more emphasis on capital-growth execution.

Venus Remedies Limited News

Venus Remedies Publishes Unaudited Q3 FY2025 Financial Results in Newspapers

An announcement from Venus Remedies Limited ( ($IN:VENUSREM) ) is now available. Venus Remedies Limited has notified the...

20d ago

Venus Remedies Closes Trading Window Ahead of December 2025 Results

Venus Remedies Limited ( ($IN:VENUSREM) ) has issued an update. Venus Remedies Limited has announced that, in accordance...

2M ago

Venus Remedies Opens Special Window for Share Transfer Requests

Venus Remedies Limited ( ($IN:VENUSREM) ) has shared an update. Venus Remedies Limited has announced the opening of...

2M ago

Venus Remedies Completes AMR Licensing Milestones with Final Payment

Venus Remedies Limited ( ($IN:VENUSREM) ) has shared an update. Venus Remedies Limited has successfully completed all commercial...

2M ago

Venus Remedies Ensures Compliance with SEBI Regulations

An announcement from Venus Remedies Limited ( ($IN:VENUSREM) ) is now available. Venus Remedies Limited has announced compliance...

4M ago

Venus Remedies Aligns with SEBI’s Investment Ease Initiative

Venus Remedies Limited ( ($IN:VENUSREM) ) has provided an update. Venus Remedies Limited has announced the re-lodgement of...

6M ago

Venus Remedies Announces AGM Notice Publication

Venus Remedies Limited ( ($IN:VENUSREM) ) just unveiled an announcement. Venus Remedies Limited has announced a newspaper publication...

7M ago

Venus Remedies Ensures Compliance with SEBI Regulations

Venus Remedies Limited ( ($IN:VENUSREM) ) has provided an announcement. Venus Remedies Limited has submitted a compliance certificate...

11M ago

VENUSREM FAQ

What was Venus Remedies Limited’s price range in the past 12 months?

Venus Remedies Limited lowest stock price was ₹277.85 and its highest was ₹872.80 in the past 12 months.

What is Venus Remedies Limited’s market cap?

Venus Remedies Limited’s market cap is ₹10.06B.

When is Venus Remedies Limited’s upcoming earnings report date?

Venus Remedies Limited’s upcoming earnings report date is Jun 03, 2026 which is in 103 days.

How were Venus Remedies Limited’s earnings last quarter?

Venus Remedies Limited released its earnings results on Jan 29, 2026. The company reported ₹19.137 earnings per share for the quarter, beating the consensus estimate of N/A by ₹19.137.

Is Venus Remedies Limited overvalued?

According to Wall Street analysts Venus Remedies Limited’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does Venus Remedies Limited pay dividends?

Venus Remedies Limited pays a Annually dividend of ₹3 which represents an annual dividend yield of N/A. See more information on Venus Remedies Limited dividends here

What is Venus Remedies Limited’s EPS estimate?

Venus Remedies Limited’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Venus Remedies Limited have?

Venus Remedies Limited has 13,366,988 shares outstanding.

What happened to Venus Remedies Limited’s price movement after its last earnings report?

Venus Remedies Limited reported an EPS of ₹19.137 in its last earnings report, beating expectations of N/A. Following the earnings report the stock price went up 3.237%.

Which hedge fund is a major shareholder of Venus Remedies Limited?

Currently, no hedge funds are holding shares in IN:VENUSREM

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

Venus Remedies Limited

Venus Remedies Limited develops and markets pharmaceutical products in India and internationally. The company offers its products in various therapeutic areas, such as analgesic, analgesic and antipyretic, anti-diabetic, antibiotic, anticoagulant, cardiac, disinfectant and antiseptic, gastro therapy, hand sanitizers, hormones, iron supplements, neurology, oncology, pain management, respiratory, skin and wound care, stress reliever, urology, and vitamins/minerals/nutrients, as well as antimicrobial resistance products. It also provides disinfectants; and a portfolio of herbal products. Venus Remedies Limited was incorporated in 1989 and is headquartered in Panchkula, India.